Abstract
CNS relapse is reported in 2-5% of diffuse large B-cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, a challenging population to treat given their commonly associated comorbidities. A retrospective analysis was performed of 270 DLBCL patients >80 years treated between 2004 and 2013 in two multicentre phase II LYSA trials (LNH03-7B, LNH09-7B) evaluating the addition of rituximab or ofatumumab to mini-CHOP as front-line therapy. No patients received CNS prophylaxis. CNS relapse was evaluated according to cumulative incidence, patient characteristics, risk factors, and survival. Median age was 83 years (range: 79-95). After a median follow-up of 28.7 months, eight patients had CNS relapse (3.0%). Median time between inclusion and CNS relapse was 19.2 months (range: 3.2-32.6). Patients survived a median of 1.5 months after CNS relapse (range: 0.4-4.1). Median OS from relapse was significantly lower in CNS relapse patients (1.5 months, 95% CI: 0.4-3.5) compared to patients with non-CNS relapse (6.6 months; 95% CI: 4.6-11.9). No baseline characteristics were associated with CNS relapse. The proportion of patients ...Continue Reading
References
Aug 15, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C HaiounF Reyes
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Aug 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HollenderH Holte
Aug 16, 2003·Blood·Herve TillyUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P FeugierB Coiffier
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Oct 5, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V BoehmeN Schmitz
Dec 11, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ThieblemontB Coiffier
Jan 16, 2009·Blood·Volkmar BoehmeMichael Pfreundschuh
Oct 29, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D VillaK J Savage
Jun 22, 2010·Cancer·Jeremy S AbramsonEphraim P Hochberg
Apr 13, 2011·The Lancet Oncology·Frédéric PeyradeUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators
Oct 13, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N SchmitzM Pfreundschuh
Aug 1, 2012·The Lancet Oncology·Frédéric PeyradeAntoine Thyss
Aug 2, 2012·British Journal of Haematology·Hany R GuirguisRena Buckstein
Dec 19, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H HolteM Eriksson
Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A TrebouetR Houot
Sep 17, 2013·British Journal of Haematology·Andrew McMillanUNKNOWN British Committee for Standards in Haematology
Oct 15, 2014·British Journal of Haematology·Andrés J M FerreriFederico Caligaris-Cappio
Feb 3, 2016·Blood·Kerry J SavageRandy D Gascoyne
Jul 7, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert SchmitzKerry J Savage
Jan 4, 2017·The Lancet. Haematology·Frédéric PeyradeFabrice Jardin
May 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N SchmitzM Pfreundschuh
Citations
Jul 16, 2019·Expert Review of Hematology·Elisa SantambrogioUmberto Vitolo
Jun 22, 2019·British Journal of Haematology·Toby A EyreChris S R Hatton
May 21, 2020·British Journal of Haematology·Pamela McKayUNKNOWN British Society of Haematology
Jun 8, 2017·Hematological Oncology·Catherine ThieblemontThierry Molina
Jul 1, 2020·Terapevticheskiĭ arkhiv·A U MagomedovaS K Kravchenko
Mar 14, 2021·British Journal of Haematology·Raul CordobaToby A Eyre